Acuta Capital Partners
11
105M
11
5
- Areas of investment
Summary
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Acuta Capital Partners, startups are often financed by Xeraya Capital, OrbiMed, Kearny Venture Partners. The meaningful sponsors for the fund in investment in the same round are Vivo Capital, RA Capital Management, Puissance Capital.
We also calculated 3 valuable employees in our database.
The top amount of exits for fund were in 2016. Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2017.
Among the most popular fund investment industries, there are Therapeutics, Pharmaceutical. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline ViewRay, Kadmon
Investments analytics
Analytics
- Total investments
- 11
- Lead investments
- 0
- Exits
- 5
- Investments by industry
- Biotechnology (11)
- Health Care (6)
- Therapeutics (3)
- Biopharma (3)
- Pharmaceutical (3) Show 6 more
- Investments by region
-
- United States (10)
- Ireland (1)
- Peak activity year
- 2020
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Group Appearance index
- 1.00
- Avg. company exit year
- 6
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Pyxis Oncology | 30 Mar 2021 | Biotechnology, Health Care, Pharmaceutical | Early Stage Venture | 152M | United States, Massachusetts, Boston |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.